

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2022 March 15; 14(3): 547-747



REVIEW

- 547** Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives
Majumder S, Shivaji UN, Kasturi R, Sigamani A, Ghosh S, Iacucci M
- 568** Barrett's esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies
Choi KKH, Sanagapalli S
- 587** Gut and liver involvement in pediatric hematolymphoid malignancies
Devarapalli UV, Sarma MS, Mathiyazhagan G
- 607** Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review
Vij M, Puri Y, Rammohan A, G G, Rajalingam R, Kaliamoorthy I, Rela M

MINIREVIEWS

- 628** Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma
Ignatova EO, Kozlov E, Ivanov M, Mileyko V, Menshikova S, Sun H, Fedyanin M, Tryakin A, Stilidi I
- 646** Evolving roles of magnifying endoscopy and endoscopic resection for neoplasia in inflammatory bowel diseases
Akiyama S, Sakamoto T, Steinberg JM, Saito Y, Tsuchiya K
- 654** Colorectal cancer carcinogenesis: From bench to bedside
Currais P, Rosa I, Claro I

ORIGINAL ARTICLE

Basic Study

- 664** O⁶-methylguanine DNA methyltransferase is upregulated in malignant transformation of gastric epithelial cells *via* its gene promoter DNA hypomethylation
Chen YX, He LL, Xiang XP, Shen J, Qi HY
- 678** RNA-Seq profiling of circular RNAs in human colorectal cancer 5-fluorouracil resistance and potential biomarkers
Cheng PQ, Liu YJ, Zhang SA, Lu L, Zhou WJ, Hu D, Xu HC, Ji G
- 690** Cost-effective low-coverage whole-genome sequencing assay for the risk stratification of gastric cancer
Ye LP, Mao XL, Zhou XB, Wang Y, Xu SW, He SQ, Qian ZL, Zhang XG, Zhai LJ, Peng JB, Gu BB, Jin XX, Song YQ, Li SW

Retrospective Study

- 703** Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy
Rossi G, Altabella L, Simoni N, Benetti G, Rossi R, Venezia M, Paiella S, Malleo G, Salvia R, Guariglia S, Bassi C, Cavedon C, Mazzarotto R
- 716** Pancreatic head *vs* pancreatic body/tail cancer: Are they different?
Sun K, Mylavarapu C, Crenshaw A, Zhang Y, Hsu E, Xu J, Niravath M, Jones SL, Ordonez A, Abdelrahim M
- 724** Clinical efficacy and prognostic risk factors of endoscopic radiofrequency ablation for gastric low-grade intraepithelial neoplasia
Wang NJ, Chai NL, Tang XW, Li LS, Zhang WG, Linghu EQ

SYSTEMATIC REVIEWS

- 734** Association of *Blastocystis hominis* with colorectal cancer: A systematic review of *in vitro* and *in vivo* evidences
Kumarasamy V, Atroosh WM, Anbazhagan D, Abdalla MMI, Azzani M

LETTER TO THE EDITOR

- 746** Re: Association between intestinal neoplasms and celiac disease - beyond celiac disease and more
Okumura K

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Colm A O'Morain, AGAF, DSc, FACG, FRCP, MBChB, MD, MSc, Full Professor, Health Sciences, RCPI, Dublin Dublin 18, Ireland. colmomorain@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*, Production Department Director: *Xiang Li*, Editorial Office Director: *Ya-Juan Ma*.

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

PUBLICATION DATE

March 15, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Association of *Blastocystis hominis* with colorectal cancer: A systematic review of *in vitro* and *in vivo* evidences

Vinoth Kumarasamy, Wahib Mohammed Atroosh, Deepa Anbazhagan, Mona Mohamed Ibrahim Abdalla, Meram Azzani

Specialty type: Oncology

Provenance and peer review:

Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Farouk S

Received: May 17, 2021

Peer-review started: May 17, 2021

First decision: July 4, 2021

Revised: July 16, 2021

Accepted: February 22, 2022

Article in press: February 22, 2022

Published online: March 15, 2022



Vinoth Kumarasamy, Deepa Anbazhagan, Department of Microbiology and Parasitology, Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jenjarom 42610, Selangor, Malaysia

Vinoth Kumarasamy, Department of Preclinical Sciences, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang 43000, Selangor, Malaysia

Wahib Mohammed Atroosh, Department of Parasitology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Wilayah Persekutuan, Malaysia

Wahib Mohammed Atroosh, Department of Microbiology and Parasitology, Faculty of Medicine and Health Sciences, University of Aden, Aden 00, Yemen

Mona Mohamed Ibrahim Abdalla, Human Biology Department, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia

Meram Azzani, Department of Community Medicine, Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jenjarom 42610, Selangor, Malaysia

Corresponding author: Meram Azzani, PhD, Senior Lecturer, Department of Community Medicine, Faculty of Medicine, Bioscience and Nursing, MAHSA University, Bandar Saujana Putra, Jenjarom 42610, Selangor, Malaysia. dr_memeazzani@yahoo.com

Abstract

BACKGROUND

Recently, there have been several findings that showed intestinal colonisation of *Blastocystis hominis* (*Blastocystis*) as a risk factor to the worsening of colorectal cancer (CRC). However, studies have shown controversial results in the pathogenicity of *Blastocystis*.

AIM

To review systematically the evidence available on the association between CRC and *Blastocystis* and the prevalence of *Blastocystis* in CRC patients and to investigate cytopathic and immunological effects of *Blastocystis* in *in vitro* and *in vivo* studies.

METHODS

PRISMA guidelines were utilised in conducting this systematic review. Original

articles published before February 2, 2020 were included. PubMed, Science Direct, Scopus and Google scholar databases were searched. Manual searching was carried out to find articles missed during the online search.

RESULTS

Out of 12 studies selected for this systematic review, seven studies confirmed the prevalence of *Blastocystis* and found it to be between 2%-28% in CRC patients, whereby subtype 1 and subtype 3 were predominantly seen. A total of four studies employing *in vitro* human colorectal carcinoma cell line study models showed significant cytopathic and immunological effects of *Blastocystis*. In addition, one *in vivo* experimental animal model study showed that there was a significant effect of infection with *Blastocystis* on exacerbation of colorectal carcinogenesis.

CONCLUSION

Blastocystis is a commonly identified microorganism in CRC patients. These studies have provided supportive data that *Blastocystis* could exacerbate existing CRC *via* alteration in host immune response and increased oxidative damage. Future studies of CRC and *Blastocystis* should attempt to determine the various stages of CRC that are most likely to be associated with *Blastocystis* and its relationship with other intestinal bacteria.

Key Words: *Blastocystis hominis*; Colorectal cancer; Cytopathic effect; Immunological effect

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Certain gut microorganisms are known to be important factors associated with initiation and development of colorectal cancer (CRC). However, data on the roles of parasites are vague and restricted. *Blastocystis hominis* (*Blastocystis*) is one of the most commonly recovered microorganisms in faecal specimens, and its widespread presence is found in CRC patients. This systematic review aims to quantify the studies published so far that revealed the association of *Blastocystis* and CRC. We sought to identify the prevalence of *Blastocystis* and its subtypes among CRC patients, *in vitro* studies using *Blastocystis* antigen and *in vivo* studies using animal models.

Citation: Kumarasamy V, Atroosh WM, Anbazhagan D, Abdalla MMI, Azzani M. Association of *Blastocystis hominis* with colorectal cancer: A systematic review of *in vitro* and *in vivo* evidences. *World J Gastrointest Oncol* 2022; 14(3): 734-745

URL: <https://www.wjgnet.com/1948-5204/full/v14/i3/734.htm>

DOI: <https://dx.doi.org/10.4251/wjgo.v14.i3.734>

INTRODUCTION

Blastocystis hominis (*Blastocystis*) is one of the most commonly recovered microorganisms in faecal specimens, and its widespread presence is found in colorectal cancer (CRC) patients[1]. Its distribution is known to be prevalent in both rural and urban areas[2]. This microorganism has been in discussion since early 1900s[3,4]; however, the taxonomic position of *Blastocystis* remains unanswered. *Blastocystis* treatment is often difficult due to its drug resistance and the failure of the host defenses to counter the infection[5]. Previous studies suggest that *Blastocystis* is a common and diverse element of microbiota in human host, as it has been highly prevalent in healthy individuals[6-8]. *Blastocystis* is commonly found in both patients with gastrointestinal symptoms and in healthy people widely across the world. More recently, researchers consider *Blastocystis* as an emerging zoonotic disease, and its pathogenic potential in human is somewhat controversial[9]. Although accumulating data suggest that *Blastocystis* is a pathogen, the pathogenic role in humans is still a matter of debate.

It is suggested that around 20% of cancer reported worldwide could have been due to infectious agents[10,11]. Viruses such as hepatitis B virus, human papilloma virus and Epstein-Barr virus have been associated with carcinogenesis. Various other bacteria also have been described previously to exacerbate cancer[12]. There are numerous epidemiological evidences that strongly support the fact that parasites can be a factor of various malignant tumours[13], but it is challenging to validate this relationship. Previously, a review article highlighted the correlation of various protozoan parasites including *Blastocystis* with carcinogenesis[13]. In addition, there was a case report in India that demonstrated a possible association of subtype 3 *Blastocystis* in the worsening of CRC[14].

There are a few other systematic reviews on the interventional studies done on *Blastocystis*, but we did not find any systematic reviews on the association between *Blastocystis* and CRC. Therefore, this systematic review aimed to (1) identify prevalence of *Blastocystis* in CRC patients; (2) review *in vitro* colorectal carcinoma cell line study models on the cytopathic and immunological effects of *Blastocystis* antigens; and (3) review an *in vivo* experimental animal model study to investigate the effect of infection with *Blastocystis* on exacerbation of colorectal carcinogenesis.

MATERIALS AND METHODS

PRISMA guidelines were utilised in conducting this review[15].

Eligibility criteria

Original articles that reported the prevalence and association of *Blastocystis* subtypes with CRC patients, *in vitro* studies using *Blastocystis* antigen and an *in vivo* study using an animal model published before February 2, 2020 were included.

Exclusion

Articles that reported the association of *Blastocystis* with cancer in general without specific findings on its association with CRC, reviews papers, conference proceedings and case reports were excluded from this review.

Search

PubMed, Science Direct, Scopus and Google scholar databases were searched.

The various keywords used were: *Blastocystis* infection and CRC and their MESH terms and synonyms. Manual searching through reference lists of included journal articles was done to find the missed studies during online search.

Study selection

We identified 872 papers in the initial screening (Figure 1).

Identification

First, two authors developed a search strategy with different key words and their synonyms. All articles were moved to the Endnote X7 software (Clarivate Analytics, Philadelphia, PA, United States), and 146 duplicate papers were removed. Two authors independently went through the titles and abstracts of the remaining 726 papers. Subsequently, a total of 22 papers were retained for full text review. The eligibility of retained papers was evaluated by two other authors. Authors checked the reference lists of all included articles for any relevant studies that met this systematic review inclusion criteria and had not been found during the database searches.

After full review of the 22 papers, 12 were selected. All authors have completed data extraction and agreed eligibility of included papers (Figure 1).

Quality assessment

For *in vivo* studies, the quality of the studies was assessed using Quasi experimental appraisal tool[16], which contained nine questions. For *in vitro* studies, checklist of Systematic Review Center for Laboratory Animal Experimentation's Risk of Bias tool for assessing risk of bias as quality assessment was used[17]. The quality of all included studies was acceptable.

Data extraction

The data extracted included author-year, country, sampling, setting, methods, results and study conclusion (Table 1).

RESULTS

Prevalence of Blastocystis in CRC patients

Based on the seven reviewed articles, the prevalence of *Blastocystis* sp. in CRC patients were found to be between 2.8%-46.7%, whereby subtype 1 and subtype 3 were predominantly isolated.

A study by Esteghamati *et al*[35] evaluated the prevalence of *Blastocystis* in 85 cancer patients, including 39 CRC and 46 cancers outside gastrointestinal tract (COGT). In this study, *Blastocystis* was identified in 11/39 (28.2%) among CRC group. Another study in China by Zhang *et al*[18] showed the prevalence of *Blastocystis* in 4 among 49 (8.1%) patients with CRC. In another study conducted in Saudi Arabia, the prevalence of *Blastocystis* among CRC patients was 29.7%[19]. Subtype I was the

Table 1 Data extraction table

No.	Ref.	Country	Sampling	Setting	Method	Main results	Conclusion
					Please note: (1) Main outcomes assessed; (2) If the protocol is published; and (3) If risk of bias is reported		
Prevalence studies							
1	Esteghamati <i>et al</i> [35], 2019	Tehran, Iran	Study design: cross-sectional. Study duration: July 2016 and November of 2017. Sample size (190): 80 patients (Primary Immunodeficiency), 85 (cancer patients) and 25 (organ transplant recipients)	3 hospitals in in Tehran, Iran	The aim of this study to determine the prevalence of intestinal parasites in 3 different groups of patients referred to 3 hospitals. Method used for parasite identification: Conventional methods, nested PCR and amplification of the <i>18S rRNA</i> gene	The prevalence of <i>Blastocystis</i> hominis among CRC patient was 13/39 (28.2%)	The prevalence of <i>Blastocystis hominis</i> was found high in cancer patients, especially CRC patients
2	Zhang <i>et al</i> [18], 2017	China	Sample size: 381 faecal specimens were collected from cancer patients including CRC. Study duration: 2016 to 2017	Tumor Hospitalof Harbin Medical University	The aim of this study to determine the prevalence and genotypes/subtypes- <i>Blastocystis</i> in CP and analysed for the <i>Blastocystis</i> by PCR amplifying and sequencing	Prevalence of <i>Blastocystis</i> was 4 (8.1%) among CRC patient	<i>Blastocystis</i> subtype 1 and 3 have been identified in humans and animals
3	Mohamed <i>et al</i> [19], 2017	Saudi Arabia	Total sample size: 218. Two groups of participants: (1) CP (138) of which 74 had CRC and 46 had cancers outside gastrointestinal tract; and (2) NCP (80). Exclusion criteria: (1) Patient started chemotherapy regime; and (2) Receiving any anti-parasitic medication. Study duration: 2013-2015	King Abdulla Medical city (KAMC), Makkah	Case control study design: Aim, to determine the prevalence of <i>Blastocystis</i> among CRC patients compared to patients who had cancers outside gastrointestinal tract and control group. Obtained <i>Blastocystis</i> isolates were grouped into 2 categories (A and C), then subtyped into 3 various subtypes; subtype-I, subtype-II and subtype-V	Prevalence of <i>Blastocystis</i> among CRC = 22 (29%). <i>Blastocystis</i> infection frequency was significantly different between CP group and NC group. There was a higher probability of <i>Blastocystis sp.</i> among CP. Subtype I was the common subtype among CRC patients (54.5%). Interestingly, an association risk between <i>Blastocystis</i> subtype 1 with a greater risk of association in CRC group	The study revealed a probable association between subtype 1 of <i>Blastocystis</i> and CRC
4	Toychiev <i>et al</i> [20], 2018	Uzbekistan	A total sample of 400 participants, two groups of participants: (1) 200 CRC patients; and (2) 200 of Tashkent residents (without any gastrointestinal tract complaints). Exclusion criteria: (1) patient had problems with stool sample collection; and (2) received any treatment 2-3 wk before the study. Study duration: 2015-2017	Research Institute of Epidemiology, Microbiology and Infectious Diseases and the Research Center of Oncology, Tashkent, Uzbekistan, during the period	Study design: Prospective cohort: Prevalence of some parasites including <i>Blastocystis sp.</i> in CRC patients before and after surgery and chemotherapy compared to control group. Methods: “3 stool samples for parasitological examination were taken at 2-d intervals during CRC diagnosis before and after surgery and chemotherapy”	A significantly higher prevalence of protozoa was found in CRC patients than in control population “the prevalence of <i>Blastocystis</i> in CRC patients is 4 times as high as in the control population. The overall prevalence of <i>Blastocystis sp.</i> was 2.8% and was higher than the other protozoa”	Data revealed a potential role for <i>Blastocystis sp.</i> in CRC pathogenesis
5	Kumarasamy <i>et al</i> [21], 2014	Malaysia	Sample size: 425 patients who go through diagnostic colonoscopy. faecal samples and colonic washouts were obtained from 221 control patients and 204 patients	University of Malaya Medical Centre	To determine the <i>Blastocystis</i> genotype present by comparing the prevalence using colonic washouts and faecal samples PCR and standard stool culture. Both techniques were used to detect <i>Blastocystis</i> from control and	The prevalence of <i>Blastocystis</i> was 15.29% (65/425). “Colonic washouts and faecal samples showed 12.24% (<i>n</i> = 52) and 5.65% (<i>n</i> = 24) of <i>Blastocystis</i> infection respectively”. A total of 43 individuals were positive for <i>Blastocystis</i> in CRC patients and	<i>Blastocystis sp.</i> is common in CRC patients. Subtype 3 is the most common genotype in the infected individuals

			with CRC. Study duration: 2010 and 2012		patients with CRC.	was significantly higher compared to control group. Subtype 3 was predominant compared to other subtypes. It was significantly higher in CRC group as compared with control group	
6	Chandramathi <i>et al</i> [1], 2012	Malaysia	Stool samples were obtained from 46 and 15 breast cancer and CRC patients, respectively	Department of Parasitology, Faculty of Medicine, University of Malaya	Aim: To investigate whether intestinal parasites can be an opportunistic infection in breast cancer and CRC patients who are undergoing chemotherapy treatment. Molecular detection of microsporidia species was done using a PCR technique. The presence of <i>Blastocystis hominis</i> was further confirmed by culturing stool samples	This study found that 7 out of 15 CRC patients were positive <i>Blastocystis</i> in various chemotherapy cycles accounting for 46.7%	<i>Blastocystis hominis</i> and microsporidia could appear as opportunistic infections during chemotherapy treatment of CP. This infection may diminish the efficacy of chemotherapy treatments and consequently advance the progression of cancer
7	Majeed <i>et al</i> [22], 2019	Iraq	116 faecal specimens with <i>Blastocystis</i> and <i>Helicobacter pylori</i> infection, 15 biopsy specimens from CRC patients	Middle Technical University/Baghdad 1st Feb 2018-15th June 2018	Faecal specimens were screened for <i>Blastocystis</i> and <i>Helicobacter pylori</i> . Direct DNA sequencing was done to evaluate mutations in CRC-associated molecular pathways	Prevalence of <i>Blastocystis</i> infection statistically insignificant in various age groups. Prevalence of <i>Blastocystis</i> infection was more in females [females 29 (46.9 %), males 22(43.1%)]. Prevalence of mixed infection (<i>Blastocystis</i> and <i>Helicobacter pylori</i>) was 27 (23.32%)	Prevalence of <i>Blastocystis</i> infection was more in females. <i>KRAS</i> and <i>TP53</i> gene mutation was observed in the CRC patients with mixed infection (<i>Blastocystis</i> and <i>H. pylori</i>)
<i>In vitro</i> studies							
8	Chandramathi <i>et al</i> [7], 2010	Malaysia	<i>In vitro</i> study model. PBMCs were isolated from blood collected from healthy persons. Solubilised antigen of <i>Blastocystis</i> isolate was obtained from a human subject. Human colorectal carcinoma cell line, HCT116, was used	University of Malaya, Kuala Lumpur	Effect solubilised antigen of <i>Blastocystis</i> on the HCT116 proliferation quantified. Gene expressions of certain genes in HCT116 and PBMCs evaluated <i>via</i> real-time reverse transcription PCR. PBMCs were isolated from blood using Histopaque technique. Cell proliferations were measured using MTT assay	Increased number of PBMCs/ HCT116 cells observed with <i>Blastocystis</i> antigen. <i>IFN-γ</i> and <i>TNF-α</i> were downregulated and <i>IL-6</i> , <i>IL-8</i> and <i>NF-κB</i> , <i>p53</i> were upregulated in the PBMCs treated with the antigen. <i>IFN-γ</i> was downregulated and <i>IL-6</i> and <i>NF-κB</i> was upregulated in HCT116 cells	Solubilised antigen of <i>Blastocystis</i> could facilitate increased number of PBMCs/ HCT116 cell and has the ability to downregulate immune cell responses
9	Chan <i>et al</i> [23], 2012	Malaysia	<i>In vitro</i> study model. Solubilised antigen of <i>Blastocystis</i> isolate was obtained from symptomatic and asymptomatic human subject. HCT116 was used	University of Malaya, Kuala Lumpur	Effects of solubilised antigen of <i>Blastocystis</i> isolate was obtained from symptomatic and asymptomatic human subject on HCT116. Gene expressions of certain genes in HCT116 and PBMCs evaluated <i>via</i> real-time reverse transcription PCR	Increased number of HCT116 cells observed with symptomatic <i>Blastocystis</i> antigen. Th2 cytokines/ <i>CTSB</i> were upregulated in HCT116. <i>NF-κB</i> was observed upregulated in HCT116 exposed to symptomatic <i>Blastocystis</i> antigen	Solubilized antigen of <i>Blastocystis</i> from symptomatic individual was more virulent than that in asymptomatic. Higher inflammatory reaction and increased proliferation of cancer cells was observed
10	Kumarasamy <i>et al</i> [24], 2013	Malaysia,	<i>In vitro</i> study model using HCT116 treated with solubilised <i>Blastocystis</i> antigen from 5 <i>Blastocystis</i> subtypes	University Malaya research Lab	<i>In vitro</i> study. HCT116 treated with solubilised antigen from <i>Blastocystis</i> . Following Assays: Proliferation of the cell line, HCT116 on exposure to different <i>Blastocystis</i> subtypes; Gene expression profile of apoptotic genes like <i>p53</i> and <i>CTSB</i> ; Transcription factor gene expression profile	<i>Blastocystis</i> subtypes (5) increased the proliferation of HCT116, especially subtype 3. <i>Blastocystis</i> antigen caused the upregulation of Th2 and Th1 cytokines, and downregulation of <i>IFN-γ</i> and <i>p53</i> in HCT116 cells. <i>Blastocystis</i> antigen caused a higher stimulation of gene expression of <i>CTSB</i> and <i>TGF-β</i> genes	Infection with <i>Blastocystis</i> caused exacerbation of existing colon cancer cells. The effect may be due to weakening of the cellular immune response and dysregulation of <i>IFN-γ</i> and <i>p53</i> expression. Infection with <i>Blastocystis</i> subtype 3 has a higher pathogenic potential

11	Ahmed <i>et al</i> [25], 2019	Cairo, Egypt	Seven <i>Blastocystis</i> isolates were from stools specimen from patients with early diagnosed CRC (Oncology and Surgery and Colonoscopy unit) of a Hospital in Egypt. The different groups were: Group I (GI), 12 isolates from infected non-CRC; Group II (GII), 6 from infected symptomatic patients and Group III (GIII), 6 from infected non-symptomatic carriers	Department of Parasitology lab, Faculty of Medicine, Ain Shams University, Cairo, Egypt	Aim: To investigate some phenotypic characters like the surface ultrastructure, protein profiles and protease activity of <i>Blastocystis</i> from three different clinical groups. Techniques performed: Scanning electron microscopy to study morphology of the organism; SDS-PAGE to analyse the <i>Blastocystis</i> protein profiles and their protease activities	Observations: All CRC <i>Blastocystis</i> isolates showed a very rough intensely folded surface when compared to less rough and smooth surface of isolates from symptomatic and asymptomatic and non-CRC isolates; SDS-PAGE showed presence of 2 protein bands of 230 and 32 KDa in 42.9% of <i>Blastocystis</i> CRC isolates and these proteins were absent in Non-CRC isolates. When the protease activity of the parasite was tested, no significant difference existed between isolates of the three groups	There was significant difference in the surface structure and the protein profiles between different clinical isolates of <i>Blastocystis</i> . Differences indicate that it may be: (1) secondary to the altered gut environment in the presence of CRC or (2) indicators of a different pathogenic potential of the parasite in inducing malignancy
<i>In Vivo</i> studies							
12	Kumarasamy <i>et al</i> [26], 2017	Malaysia	Different specimens collected: Blood, urine, faecal samples and gastrointestinal tract sections from 24 male Wistar rats. Age of the rats: 3 wk. Weight of each rat: Average of 65 g/rat	University Malaya research Lab	<i>In vivo</i> experimental study. Aim: To investigate the effect of infection with <i>Blastocystis</i> cyst on exacerbation of carcinogenesis. Twenty-four rats divided into different groups for the study (4 groups, 6 rats each): Control group, AOM group, group inoculated with <i>Blastocystis</i> cyst, the group inoculated with <i>Blastocystis</i> cyst and AOM injection. Body weights recorded once a week. Rat faecal samples screened for presence of <i>Blastocystis</i> post-inoculation. Histopathological assessment of the rat colon for aberrant crypts. Urine and blood samples assessed for oxidative stress	Observations: lower body weight showed by <i>Blastocystis</i> infected rats than rats infected with <i>Blastocystis</i> and injected with AOM ($P < 0.05$). Stools from AOM-rats with <i>Blastocystis</i> infection were softer and watery compared to the AOM-rats without <i>Blastocystis</i> infection. <i>Blastocystis</i> was present in the stool of all infected rats from Day 3 to 7 post-inoculation. All the rats injected with AOM developed numerous abnormal, hyperplastic colonic crypts. Co-administration of <i>Blastocystis</i> cyst showed a 1.6-fold increase in the number of crypts when compared with control rats treated with AOM only. Two of the co- <i>Blastocystis</i> infected AOM-rats were found to have adenomas. Major dysplasia and presence of hyperplastic aberrant crypts were observed in rats injected with AOM and co-infected with <i>Blastocystis</i>	<i>Blastocystis</i> infection considerably enhanced the AOM-induced carcinogenesis because of the oxidative damage of the intestinal epithelium

AOM: Azoxymethane; CP: Cancer patients; CRC: Colorectal cancer; CTSB: Cathepsin B; IFN: Interferon; IL: Interleukin; NCP: Non cancer patients; NF-kB: Nuclear factor kappa B; PBMCs: Peripheral blood mononuclear cells; PCR: Polymerase chain reaction; SDS-PAGE: Sodium dodecyl sulphate–polyacrylamide gel electrophoresis.

predominant (54.5%) among CRC patients, while subtype II was predominant (43.7%) among COGT patients[19]. Higher prevalence of intestinal helminths and protozoa was observed in CRC patients than in the control population in a study conducted in Uzbekistan. The prevalence of *Blastocystis* in CRC patients was four times higher than that in the control population. The overall prevalence of *Blastocystis* (2.8%) was significantly higher than the other protozoa[20]. In a study by Kumarasamy *et al* [21] in Malaysia, among 221 control patients and 204 CRC patients with colorectal malignancies, the overall prevalence of *Blastocystis* infection was 15.29% (65/425). A total of 43 (21.08%) samples were positive for *Blastocystis* infection in CRC patients and was significantly higher compared to normal individuals ($n = 22$, 9.95%, $P < 0.01$). Subtype 3 was present at higher levels compared to other subtypes detected in both groups and was significantly higher in CRC patients as compared with control patients[21].

Another study was designed to investigate the emergence of *Blastocystis* and Microsporidia infections in breast and CRC patients undergoing chemotherapy treatment. This study found that 7 out of 15 CRC




Figure 1 Search strategy.

patients were positive *Blastocystis* in various chemotherapy cycles, accounting for 46.7%. However, the researchers did not mention whether the isolate was from the same patients in different cycles[1]. In a study carried out in Iraq, stool samples from 116 patients with *Blastocystis* and *H. pylori* infections were investigated. Fifteen tissue samples of CRC were taken from 15 suspected patients out of 116 infected cases, and it was shown that the infection with *Blastocystis* and *H. pylori* was associated with pathological gene mutation in the CRC patients[22].

***In vitro* colorectal carcinoma cell line studies on the cytopathic and immunological effects of Blastocystis antigen**

Three of the reviewed articles used *in vitro* study models and observed considerable cytopathic and immunological effects induced by the solubilised antigen of *Blastocystis* to the human colorectal carcinoma cell line[7,23,24]. These findings speculated that *Blastocystis* infection may enhance the proliferation, invasiveness and metastatic properties of CRC cells. One study investigated some phenotypic characteristics of *Blastocystis* isolated from CRC patients[25].

The three *in vitro* model studies used the human colorectal carcinoma cell line HCT116 and the *Blastocystis* isolated from a human subject[7,23,24]. One of the studies demonstrated the cytopathic effect of *Blastocystis* antigen on peripheral blood mononuclear cells. This study findings showed increased cell proliferations in *Blastocystis* antigen-stimulated HCT116 cell-lines, which suggested that the infection by *Blastocystis* may facilitate the growth of colon cancer cells[7]. Another *in vitro* study showed that the five subtypes of *Blastocystis* significantly increased the proliferation of HCT116, especially subtype 3. *Blastocystis* antigen caused the upregulation of T helper (Th)2 and Th1 cytokine gene expressions, and downregulation of interferon gamma and *p53* gene expressions in HCT116 cells. In addition, *Blastocystis* antigen caused a significantly higher stimulation of Cathepsin B (CTSB) and Transforming growth factor beta (TGF- β) gene expression, which indicates the pathogenic potential of this protozoan[24]. Another study showed an increase in cell proliferation in HCT116 cells inoculated with the symptomatic *Blastocystis* antigen. Gene expression studies carried out in this research also showed a significant upregulation of Th2 cytokines, which indicates the parasites' potential in weakening the cellular immune response[23]. HCT116 cells exposed to symptomatic and asymptomatic *Blastocystis* antigen caused a significant upregulation of CTSB, which led to the postulation that the *Blastocystis* antigen may enhance the invasive and metastasis properties of CRC[23].

Another study sought to investigate some phenotypic characteristics such as the surface ultrastructure, protein profiles and protease activity of *Blastocystis* isolated from three different clinical groups: CRC patients, non-CRC symptomatic and asymptomatic infected persons. This study showed the presence of two protein bands of 230 and 32 KDa in 42.9% of *Blastocystis* CRC isolates with their complete absence from non-CRC isolates. There was no significant difference in the protease activity of the protein among isolates of the three groups, CRC and Non-CRC *Blastocystis* isolates[25].

In vivo experimental animal model to investigate the effects of infection with Blastocystis on exacerbation of colorectal carcinogenesis

An animal model study compared the effects of *Blastocystis* infected rats and rats infected with *Blastocystis* co-administered with Azoxymethane (AOM), a potent carcinogen. This finding showed that the co-administration of *Blastocystis* cyst resulted in a 1.6-fold increase in the number of colonic crypts when compared with control rats treated with AOM only. Two of the co-*Blastocystis* infected AOM rats were found to have adenomas. Major dysplasia and the presence of hyperplastic aberrant crypts were also observed in rats injected with AOM and co-infected with *Blastocystis*[26].

DISCUSSION

Blastocystis is one of the most common gut microorganisms found in healthy individuals[27]. Besides being associated with a healthy gut microbiota[27,28], *Blastocystis* infection is also known to be opportunistic in immunocompromised patients[29]. CRC is the third most common cancer diagnosed worldwide and one of the major causes of cancer-associated fatality[30]. The reason for high mortality is due to the asymptomatic progression of the disease that usually results in late diagnosis[31,32]. Certain gut microorganisms are known to be one of the important factors that had been associated with initiation and development of CRC[33]. However, data on the roles of parasites are vague and restricted. Various findings have been reported regarding the association between *Blastocystis* among CRC patients, whereby positive association was shown in all the studies[1,23,24]. Therefore, the aim of this systematic review was to quantify the studies published so far that revealed the direct association of *Blastocystis* and CRC. This paper outlines the results of a systematic review to evaluate the prevalence of *Blastocystis* in CRC patients, *in vitro* studies using *Blastocystis* antigen and an *in vivo* study using animal models.

Out of the data extracted from 12 studies relevant to this topic, all the studies showed positive association between *Blastocystis* and CRC. Prevalence studies, *in vitro* investigations and *in vivo* studies were used to evaluate the pathogenicity of *Blastocystis* with CRC.

The global prevalence of *Blastocystis* infection ranged from 1.5%-20% in developed countries, which was much less than that in developing countries, which was 30%-50% [34]. Based on our review, the prevalence of *Blastocystis* infection in CRC patients ranged between 2.8%-46.7%. It has been widely reported in the world, in developing countries such as Iran, China, Saudi Arabia, Uzbekistan and Malaysia[18-20,24,35]. The first demonstration of *Blastocystis* infection in Iran was reported in 11 CRC patients in Tehran province[35]. In Malaysia, a total of 43 samples were positive for *Blastocystis* from 204 CRC patients[21]. This study utilised colonic washout in addition to stool sample to recover the parasites. Subtype 3 *Blastocystis* was detected predominantly as compared to other subtypes[21]. Some of these findings highlighted the high prevalence of certain subtypes of *Blastocystis* among these patients [19,21]. A previous study showed that subtype 1 was the most common genotype identified (54.5%) among CRC patients[19]. DNA was extracted from *Blastocystis* cultures *via* conventional method and subtyped using multiplex polymerase chain reaction (PCR) with restriction fragment length polymorphism and sequence-tagged site primers-based PCR. In another study, subtype 3 was predominant compared to other subtypes found in both CRC patients and healthy individuals[21]. Subtype 3 is speculated as the most pathogenic subtype in symptomatic individuals[36]. Some researchers have attributed subtype 3 to be more pathogenic compared to other subtypes[37,38]. *Blastocystis* was initially screened *via in vitro* culture and conventional PCR using stool samples and colonic washouts. The presence of *Blastocystis* infection in CRC patients could be contributed by various reasons including health status. For instance, positive cases were more likely in patients with gastrointestinal symptoms compared to healthy individuals[18]. Besides, *Blastocystis* was also identified in higher frequency in immunosuppressed CRC patients who were undergoing chemotherapy treatment[1,18].

A total of three *in vitro* studies were carried out using colorectal carcinoma cell line models to study cytopathic and immunological effects of *Blastocystis* antigen[7,23,24]. Some of the research studies suggested that solubilised antigen of *Blastocystis* could facilitate the exacerbation of CRC cells, HCT116 [7,23]. In another study by Kumarasamy *et al*[24], *Blastocystis* subtype 3 stimulated significantly higher CTSB and TGF- β gene expression in HCT116, which indicates the pathogenic potential of this protozoan. Result of *in vitro* studies that were performed in Malaysia were similar[7,23,24].

Blastocystis is commonly found in both patients with gastrointestinal symptoms and in healthy people widely across the world. More recently, researchers consider *Blastocystis* as an emerging zoonotic disease, and its pathogenic potential in human is unclear[9]. The pathogenic potential of *Blastocystis* was widely debated, as they are found in both symptomatic and asymptomatic patients. The significant expression of nuclear factor kappa light chain enhancer of activated B cells was observed in HCT116 exposed to *Blastocystis* antigen isolated from individuals with gastrointestinal symptoms, but such observations were not found when the colon cells treated with *Blastocystis* antigen isolated from asymptomatic individuals. This finding shows the potential pathogenicity of symptomatic *Blastocystis* in CRC patients[23]. Similarly, HCT116 cells exposed to symptomatic and asymptomatic *Blastocystis*

antigen caused a significant upregulation of *CTSB*. These gene expression findings lead to a postulation that the *Blastocystis* antigen may enhance the invasive and metastasis properties of CRC[23]. Besides, proliferation of HCT116 when exposed with *Blastocystis* antigen could be a result of higher levels of interleukin (IL)-6 and IL-8 expression[23].

Another study revealed that solubilised antigen isolated from subtype 2 and 3 isolates introduced to colon cancer cells showed significant IL-8 and IL-6 expression[24]. The production of inflammatory cytokines such as IL-8 together with reactive oxygen species could contribute to the pathogenesis of cancer[38]. In a few studies conducted previously, IL-6 expression was associated with proliferation of colon carcinoma[39,40]. Besides that, subtype 3 *Blastocystis* also triggered positive expression of *CTSB* in cancer cells. A previous study showed that *CTSB* expression is significant in CRC patients[41].

Only one study was conducted to investigate the *in vivo* effect of *Blastocystis* in Wistar rats. In parallel with *in vitro* studies, an *in vivo* study showed similar findings on the possible role of *Blastocystis* to exacerbate CRC. The results demonstrated that *Blastocystis* may cause damage to the intestinal mucosal layer and result in increased crypts formation. Furthermore, an increased oxidative stress was also observed in these rats. There have been numerous animal models of human CRC and animal model of tumour carried out *via* quantification of aberrant crypt foci[42,43]. This allows the study of gut microbiome and its role in pathogenesis. In humans, there are many potential pathogenic and non-pathogenic gut microbial infections, and various animal models have been used for such studies. Aberrant crypt foci are known as putative precancerous lesions of the colon in both animal models and humans[44,45]. Even though various studies associating *Blastocystis* and CRC were carried out *via in vitro* model using colon cancer cells, this study utilised animal model to bridge between *in vitro* findings in the laboratory and studies in humans. As such, this extensive *in vivo* study showed that *Blastocystis* had a major impact on normal intestinal function in Wistar rats resulting in damage to the intestinal mucosal layer and inducing oxidative stress, which caused increase in crypts formation in AOM-treated rat models. The study establishes that *Blastocystis* is a pathogen, and there is a need to screen cancer patients for harbouring this parasite.

This systematic review has some limitations. According to these investigations, a greater prevalence of *Blastocystis* was found in CRC patients, but the question whether increased prevalence of *Blastocystis* could be linked with increased high risk to CRC is unclear. The studies discussed in this review did not highlight the association of *Blastocystis* according to cancer stages, and it was unclear if *Blastocystis* itself could result in the initiation of malignancy as *Blastocystis* acquisition alone is insufficient for cancer development. Even though strong association between *Blastocystis* and CRC is apparent, some questions remain unanswered. Therefore, we propose future studies should focus on the pathogenicity of *Blastocystis* in various stages of CRC by concentrating on the molecular pathways involved in tumorigenesis.

CONCLUSION

In conclusion, according to various recent studies, *Blastocystis* is one of the most commonly identified microorganisms in CRC patients, whereby subtype 1 and subtype 3 were predominantly isolated. It is apparent in most cases that the prevalence is higher in developing countries compared to developed countries. These studies have provided supportive data that *Blastocystis* could exacerbate existing CRC *via* alteration in host immune response and increased oxidative damage. An *in vivo* study well-established that *Blastocystis* infections resulted in tissue damage from host inflammatory responses that may predispose the host towards neoplasm exacerbation. Upregulation of gene expression responsible for proinflammatory cytokines and downregulation of apoptotic genes was observed in *in vitro* studies. Through continued research in *Blastocystis* and CRC, we may discover new findings as well as develop new effective means of prevention. Future studies of CRC and *Blastocystis* should attempt to determine the various stages of CRC that are most likely to be associated with *Blastocystis* and its association with other intestinal bacteria. In addition, future *in vivo* studies should evaluate exposure to various subtypes of *Blastocystis*.

ARTICLE HIGHLIGHTS

Research background

Intestinal colonisation of *Blastocystis hominis* (*Blastocystis*) as a risk factor to the worsening of colorectal cancer (CRC).

Research motivation

There has been an increase in the prevalence of *Blastocystis* in CRC patients. Besides, various *in vitro* and *in vivo* studies have highlighted *Blastocystis* as an important risk factor for the worsening of CRC.

Research objectives

To perform a systematic review on all evidence on the association between CRC and *Blastocystis*.

Research methods

A systematic review of the literature was performed by searching PubMed, Science Direct, Scopus and Google scholar databases up to February 2020.

Research results

Out of 12 studies selected for this systematic review, seven studies have confirmed the prevalence of *Blastocystis*. A total of four studies employing *in vitro* human colorectal carcinoma cell line study models showed significant cytopathic and immunological effects of *Blastocystis*. One *in vivo* experimental animal model study showed that there was a significant effect of infection with *Blastocystis* on exacerbation of colorectal carcinogenesis.

Research conclusions

Blastocystis is a commonly identified microorganisms in CRC patients. These studies have provided supportive data that *Blastocystis* could exacerbate existing CRC *via* alteration in host immune response and increased oxidative damage.

Research perspectives

Future studies of CRC and *Blastocystis* should attempt to determine the various stages of CRC that are most likely to be associated with *Blastocystis* and its association with other intestinal diseases.

FOOTNOTES

Author contributions: Azzani M designed the research, performed the literature search and extracted the data; Kumarasamy V wrote the discussion and extracted the data; Atroosh WM wrote the methodology and extracted the data; Anbazhagan D wrote the results and extracted the data; Abdalla M wrote the introduction and extracted the data; All authors read and approved the final manuscript.

Conflict-of-interest statement: Dr. Azzani has nothing to disclose.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Malaysia

ORCID number: Vinoth Kumarasamy 0000-0002-8895-1796; Wahib Mohammed Atroosh 0000-0003-3809-3460; Deepa Anbazhagan 0000-0002-2527-4126; Mona Mohamed Ibrahim Abdalla 0000-0002-4987-9517; Meram Azzani 0000-0002-7939-1539.

S-Editor: Chang KL

L-Editor: Filipodia

P-Editor: Chang KL

REFERENCES

- 1 **Chandramathi S**, Suresh K, Anita ZB, Kuppusamy UR. Infections of *Blastocystis hominis* and microsporidia in cancer patients: are they opportunistic? *Trans R Soc Trop Med Hyg* 2012; **106**: 267-269 [PMID: 22340948 DOI: 10.1016/j.trstmh.2011.12.008]
- 2 **Aksoy U**, Akisü C, Bayram-Delibas S, Ozkoç S, Sahin S, Usluca S. Demographic status and prevalence of intestinal parasitic infections in schoolchildren in Izmir, Turkey. *Turk J Pediatr* 2007; **49**: 278-282 [PMID: 17990581]
- 3 **Brumpt E**. *Blastocystis hominis* n. sp. et formes voisines. *Bull Soc Pathol* 1912; **5**: 725-730
- 4 **Low GC**. Two Chronic Amoebic Dysentery Carriers treated by Emetine, with some Remarks on the Treatment of *Lamblia*, *Blastocystis* and *E. coli* Infections. *J Trop Med Hyg* 1916; **19**: 29-34
- 5 **Roberts T**, Ellis J, Harkness J, Marriott D, Stark D. Treatment failure in patients with chronic *Blastocystis* infection. *J Med Microbiol* 2014; **63**: 252-257 [PMID: 24243286 DOI: 10.1099/jmm.0.065508-0]

- 6 **Borralho PM**, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. *FEBS J* 2009; **276**: 6689-6700 [PMID: [19843160](#) DOI: [10.1111/j.1742-4658.2009.07383.x](#)]
- 7 **Chandramathi S**, Suresh K, Kuppusamy UR. Solubilized antigen of Blastocystis hominis facilitates the growth of human colorectal cancer cells, HCT116. *Parasitol Res* 2010; **106**: 941-945 [PMID: [20165878](#) DOI: [10.1007/s00436-010-1764-7](#)]
- 8 **Cirioni O**, Giacometti A, Drenaggi D, Ancarani F, Scalise G. Prevalence and clinical relevance of Blastocystis hominis in diverse patient cohorts. *Eur J Epidemiol* 1999; **15**: 389-393 [PMID: [10414382](#) DOI: [10.1023/a:1007551218671](#)]
- 9 **Basak S**, Rajurkar MN, Mallick SK. Detection of Blastocystis hominis: a controversial human pathogen. *Parasitol Res* 2014; **113**: 261-265 [PMID: [24169810](#) DOI: [10.1007/s00436-013-3652-4](#)]
- 10 **Bouvard V**, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Coglian V; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. *Lancet Oncol* 2009; **10**: 321-322 [PMID: [19350698](#) DOI: [10.1016/s1470-2045\(09\)70096-8](#)]
- 11 **zur Hausen H**. Streptococcus bovis: causal or incidental involvement in cancer of the colon? *Int J Cancer* 2006; **119**: xi-xii [PMID: [16947772](#) DOI: [10.1002/ijc.22314](#)]
- 12 **Lax AJ**. Opinion: Bacterial toxins and cancer--a case to answer? *Nat Rev Microbiol* 2005; **3**: 343-349 [PMID: [15806096](#) DOI: [10.1038/nrmicro1130](#)]
- 13 **El-Gayar EK**, Mahmoud MM. Do protozoa play a role in carcinogenesis? *Parasitol United J* 2014; **7**: 80 [DOI: [10.4103/1687-7942.149553](#)]
- 14 **Padukone S**, Mandal J, Parija SC. Severe Blastocystis subtype 3 infection in a patient with colorectal cancer. *Trop Parasitol* 2017; **7**: 122-124 [PMID: [29114493](#) DOI: [10.4103/tp.TP_87_15](#)]
- 15 **Moher D**, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**: e1000097 [PMID: [19621072](#) DOI: [10.1371/journal.pmed.1000097](#)]
- 16 **(JBI) TJBI**. Critical Appraisal Tools. [cited 1 January 2021]. Available from: <http://joannabriggs.org/research/critical-appraisal-tools.html>
- 17 **Hooijmans CR**, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. *BMC Med Res Methodol* 2014; **14**: 43 [PMID: [24667063](#) DOI: [10.1186/1471-2288-14-43](#)]
- 18 **Zhang W**, Ren G, Zhao W, Yang Z, Shen Y, Sun Y, Liu A, Cao J. Genotyping of Enterocytozoon bienersi and Subtyping of Blastocystis in Cancer Patients: Relationship to Diarrhea and Assessment of Zoonotic Transmission. *Front Microbiol* 2017; **8**: 1835 [PMID: [28983297](#) DOI: [10.3389/fmicb.2017.01835](#)]
- 19 **Mohamed AM**, Ahmed MA, Ahmed SA, Al-Semany SA, Alghamdi SS, Zagloul DA. Predominance and association risk of Blastocystis hominis subtype 1 in colorectal cancer: a case control study. *Infect Agent Cancer* 2017; **12**: 21 [PMID: [28413436](#) DOI: [10.1186/s13027-017-0131-z](#)]
- 20 **Toychiev A**, Abdujapparov S, Imamov A, Navruzov B, Davis N, Badalova N, Osipova S. Intestinal helminths and protozoan infections in patients with colorectal cancer: prevalence and possible association with cancer pathogenesis. *Parasitol Res* 2018; **117**: 3715-3723 [PMID: [30220046](#) DOI: [10.1007/s00436-018-6070-9](#)]
- 21 **Kumarasamy V**, Roslani AC, Rani KU, Kumar Govind S. Advantage of using colonic washouts for Blastocystis detection in colorectal cancer patients. *Parasit Vectors* 2014; **7**: 162 [PMID: [24708637](#) DOI: [10.1186/1756-3305-7-162](#)]
- 22 **Majeed GH**, Mohammed NS, Muhsen SS. The synergistic effect of Blastocystis hominis and H. pylori in Iraqi colorectal cancer patients. *J. Pharm. Sci. & Res* 2019; **11**: 523-526
- 23 **Chan KH**, Chandramathi S, Suresh K, Chua KH, Kuppusamy UR. Effects of symptomatic and asymptomatic isolates of Blastocystis hominis on colorectal cancer cell line, HCT116. *Parasitol Res* 2012; **110**: 2475-2480 [PMID: [22278727](#) DOI: [10.1007/s00436-011-2788-3](#)]
- 24 **Kumarasamy V**, Kuppusamy UR, Samudi C, Kumar S. Blastocystis sp. subtype 3 triggers higher proliferation of human colorectal cancer cells, HCT116. *Parasitol Res* 2013; **112**: 3551-3555 [PMID: [23933809](#) DOI: [10.1007/s00436-013-3538-5](#)]
- 25 **Ahmed MM**, Habib FSM, Saad GA, El Naggar HM. Surface ultrastructure, protein profile and zymography of Blastocystis species isolated from patients with colorectal carcinoma. *J Parasit Dis* 2019; **43**: 294-303 [PMID: [31263336](#) DOI: [10.1007/s12639-019-01092-9](#)]
- 26 **Kumarasamy V**, Kuppusamy UR, Jayalakshmi P, Samudi C, Ragavan ND, Kumar S. Exacerbation of colon carcinogenesis by Blastocystis sp. *PLoS One* 2017; **12**: e0183097 [PMID: [28859095](#) DOI: [10.1371/journal.pone.0183097](#)]
- 27 **Scanlan PD**, Stensvold CR, Rajilić-Stojanović M, Heilig HG, De Vos WM, O'Toole PW, Cotter PD. The microbial eukaryote Blastocystis is a prevalent and diverse member of the healthy human gut microbiota. *FEMS Microbiol Ecol* 2014; **90**: 326-330 [PMID: [25077936](#) DOI: [10.1111/1574-6941.12396](#)]
- 28 **Audebert C**, Even G, Cian A; Blastocystis Investigation Group, Loywick A, Merlin S, Viscogliosi E, Chabé M. Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota. *Sci Rep* 2016; **6**: 25255 [PMID: [27147260](#) DOI: [10.1038/srep25255](#)]
- 29 **Bednarska M**, Jankowska I, Pawelas A, Piwczyńska K, Bajer A, Wolska-Kuśnierz B, Wielopolska M, Welc-Faleciak R. Prevalence of Cryptosporidium, Blastocystis, and other opportunistic infections in patients with primary and acquired immunodeficiency. *Parasitol Res* 2018; **117**: 2869-2879 [PMID: [29946765](#) DOI: [10.1007/s00436-018-5976-6](#)]
- 30 **Favoriti P**, Carbone G, Greco M, Pirozzi F, Pirozzi RE, Corcione F. Worldwide burden of colorectal cancer: a review. *Updates Surg* 2016; **68**: 7-11 [PMID: [27067591](#) DOI: [10.1007/s13304-016-0359-y](#)]
- 31 **O'Connell JB**, Maggard MA, Liu JH, Etzioni DA, Ko CY. Are survival rates different for young and older patients with rectal cancer? *Dis Colon Rectum* 2004; **47**: 2064-2069 [PMID: [15657655](#) DOI: [10.1007/s10350-004-0738-1](#)]
- 32 **Siegel RL**, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. *Cancer Epidemiol Biomarkers Prev* 2012; **21**: 411-416 [PMID: [22219318](#) DOI: [10.1158/1055-9965.EPI-11-1020](#)]
- 33 **Zhu Q**, Gao R, Wu W, Qin H. The role of gut microbiota in the pathogenesis of colorectal cancer. *Tumour Biol* 2013; **34**: 1285-1300 [PMID: [23397545](#) DOI: [10.1007/s13277-013-0684-4](#)]

- 34 **Su FH**, Chu FY, Li CY, Tang HF, Lin YS, Peng YJ, Su YM, Lee SD. Blastocystis hominis infection in long-term care facilities in Taiwan: prevalence and associated clinical factors. *Parasitol Res* 2009; **105**: 1007-1013 [PMID: [19488784](#) DOI: [10.1007/s00436-009-1509-7](#)]
- 35 **Esteghamati A**, Khanaliha K, Bokharaei-Salim F, Sayyahfar S, Ghaderipour M. Prevalence of Intestinal Parasitic Infection in Cancer, Organ Transplant and Primary Immunodeficiency Patients in Tehran, Iran. *Asian Pac J Cancer Prev* 2019; **20**: 495-501 [PMID: [30803212](#) DOI: [10.31557/APJCP.2019.20.2.495](#)]
- 36 **Souppart L**, Sancier G, Cian A, Wawrzyniak I, Delbac F, Capron M, Dei-Cas E, Boorom K, Delhaes L, Viscogliosi E. Molecular epidemiology of human Blastocystis isolates in France. *Parasitol Res* 2009; **105**: 413-421 [PMID: [19290540](#) DOI: [10.1007/s00436-009-1398-9](#)]
- 37 **Ragavan ND**, Govind SK, Chye TT, Mahadeva S. Phenotypic variation in Blastocystis sp. ST3. *Parasit Vectors* 2014; **7**: 404 [PMID: [25174569](#) DOI: [10.1186/1756-3305-7-404](#)]
- 38 **Rajamanikam A**, Hooi HS, Kudva M, Samudi C, Kumar S. Resistance towards metronidazole in Blastocystis sp.: A pathogenic consequence. *PLoS One* 2019; **14**: e0212542 [PMID: [30794628](#) DOI: [10.1371/journal.pone.0212542](#)]
- 39 **Chung YC**, Chang YF. Serum interleukin-6 Levels reflect the disease status of colorectal cancer. *J Surg Oncol* 2003; **83**: 222-226 [PMID: [12884234](#) DOI: [10.1002/jso.10269](#)]
- 40 **Galizia G**, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. *Clin Immunol* 2002; **102**: 169-178 [PMID: [11846459](#) DOI: [10.1006/clin.2001.5163](#)]
- 41 **Herszényi L**, Farinati F, Cardin R, István G, Molnár LD, Hritz I, De Paoli M, Plebani M, Tulassay Z. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. *BMC Cancer* 2008; **8**: 194 [PMID: [18616803](#) DOI: [10.1186/1471-2407-8-194](#)]
- 42 **Kim J**, Ng J, Arozullah A, Ewing R, Llor X, Carroll RE, Benya RV. Aberrant crypt focus size predicts distal polyp histopathology. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 1155-1162 [PMID: [18483337](#) DOI: [10.1158/1055-9965.EPI-07-2731](#)]
- 43 **Reddy BS**. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. *Environ Mol Mutagen* 2004; **44**: 26-35 [PMID: [15199544](#) DOI: [10.1002/em.20026](#)]
- 44 **Bird RP**. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. *Cancer Lett* 1987; **37**: 147-151 [PMID: [3677050](#) DOI: [10.1016/0304-3835\(87\)90157-1](#)]
- 45 **Roncucci L**, Stamp D, Medline A, Cullen JB, Bruce WR. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. *Hum Pathol* 1991; **22**: 287-294 [PMID: [1706308](#) DOI: [10.1016/0046-8177\(91\)90163-j](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

